Table 1 Patient Characteristics
Characteristic | Patients | |||
|---|---|---|---|---|
All | LC | CRC | Other | |
(n = 30) | (n = 15) | (n = 10) | (n = 5) | |
Sex, n (%) | ||||
 M | 24 (80.0) | 12 (80.0) | 8 (80.0) | 4 (80.0) |
 F | 6 (20.0) | 3 (20.0) | 2 (20.0) | 1 (20.0) |
Age (years), median (range) | 66.5 (39–79) | 68.0 (43–79) | 62.5 (43–75) | 56.0 (39–75) |
ECOG PS, n (%) | ||||
 0–1 | 24 (80.0) | 12 (80.0) | 8 (80.0) | 4 (80.0) |
 2 | 4 (13.3) | 3 (20.0) | 0 (0.0) | 1 (20.0) |
 3 | 2 (6.7) | 0 (0.0) | 2 (20.0) | 0 (0.0) |
Stage, n (%) | ||||
 IIB-IIIA | 3 (10.0) | 2 (13.3) | 0 (0.0) | 1 (20.0) |
 IIIB-ΙΙΙC | 3 (10.0) | 2 (13.3) | 0 (0.0) | 1 (20.0) |
 IV | 22 (73.3) | 10 (66.7) | 9 (90.0) | 3 (60.0) |
Postoperative recurrence, n (%) | 2 (6.7) | 1 (6.7) | 1 (10.0) | 0 (0.0) |
Line of cancer chemotherapy at the commencement of concurrent chemotherapy, n (%) | ||||
 Adjuvant | 1 (3.3) | 0 (0.0) | 0 (0.0) | 1 (20.0) |
 First | 21 (70.0) | 9 (60.0) | 8 (80.0) | 4 (80.0) |
 Second | 3 (10.0) | 3 (20.0) | 0 (0.0) | 0 (0.0) |
 Third or higher | 5 (16.7) | 3 (20.0) | 2 (20.0) | 0 (0.0) |
Diabetes mellitus, n (%) | ||||
 Y | 7 (20.7) | 3 (20.0) | 2 (20.0) | 2 (40.0) |
 N | 23 (79.3) | 12 (80.0) | 8 (80.0) | 3 (60.0) |
MTB diagnosis, n (%) | ||||
 Before anti-CCT | 20 (66.7) | 8 (53.3) | 8 (80.0) | 4 (80.0) |
 During anti-CCT | 10 (33.3) | 7 (46.7) | 2 (20.0) | 1 (20.0) |